Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is a clinical issue in patients with epidermal growth factor receptor gene (EGFR)-mutated non-small cell lung cancer (NSCLC). The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion.
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation / LA MONICA, Silvia; Madeddu, Denise; Tiseo, Marcello; Vivo, Valentina; Galetti, Maricla; Cretella, Daniele; Bonelli, Mara; Fumarola, Claudia; Cavazzoni, Andrea; Falco, Angela; Gervasi, Andrea; Lagrasta, Costanza Anna Maria; Naldi, Nadia; Barocelli, Elisabetta; Ardizzoni, Andrea; Quaini, Federico; Petronini, Pier Giorgio; Alfieri, Roberta. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 11:7(2016), pp. 1051-63-1063. [10.1016/j.jtho.2016.03.006]
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation
LA MONICA, Silvia;MADEDDU, Denise;TISEO, Marcello;VIVO, Valentina;GALETTI, Maricla;CRETELLA, DANIELE;BONELLI, Mara;FUMAROLA, Claudia;CAVAZZONI, Andrea;FALCO, Angela;GERVASI, Andrea;LAGRASTA, Costanza Anna Maria;BAROCELLI, Elisabetta;ARDIZZONI, Andrea;QUAINI, Federico;PETRONINI, Pier Giorgio;ALFIERI, Roberta
2016-01-01
Abstract
Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is a clinical issue in patients with epidermal growth factor receptor gene (EGFR)-mutated non-small cell lung cancer (NSCLC). The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion.| File | Dimensione | Formato | |
|---|---|---|---|
|
La Monica et al JTO 2016.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
1.35 MB
Formato
Adobe PDF
|
1.35 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
